The landscape of generic drug economics in the United States is undergoing a significant transformation, largely driven by the advent…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The United States, long an outlier in global pharmaceutical pricing, is undergoing a profound transformation in its drug cost landscape,…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The U.S. pharmaceutical landscape, historically characterized by higher drug prices compared to other developed nations, is undergoing a significant transformation,…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The United States healthcare system, grappling with persistently high drug costs, has seen significant shifts in its economic landscape, particularly…
Read More
US Life Sciences Investment Woes Leave Nation Vulnerable as China Cultivates Future Big Pharma Competitors
San Diego, CA – The landscape of global biopharmaceutical innovation is undergoing a significant shift, with concerns mounting among investors…
Read More
Canada Makes History as First G7 Nation to Approve Generic Semaglutide, Sparking Global Debate on Patent Enforcement and Drug Access
In a landmark decision poised to reshape the landscape of diabetes and obesity management, Health Canada has granted authorization to…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide as Novo Nordisk Patent Lapses
In a landmark decision poised to reshape the pharmaceutical landscape and significantly impact patient access and healthcare costs, Health Canada…
Read More
UAE Becomes First Nation to Approve AstraZeneca’s Baxfendy for Uncontrolled Hypertension
The United Arab Emirates has achieved a significant milestone in pharmaceutical innovation with the Emirates Drug Establishment (EDE) granting regulatory…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide Following Novo Nordisk Patent Lapse, Paving Way for Enhanced Access and Affordability
In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read More
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
On May 12, 2025, a significant executive order signed by then-US President Donald Trump mandated the US Department of Health…
Read More
